updat model reflect recent foreign currenc chang remain top
large-cap pick medic devic sector
full-year sale tailwind like half outlin januari
base current exchang rate estim currenc favor impact
approxim abt full-year report sale benefit stem
euro compani initi forecast currency-driven tailwind full-
year sale gave guidanc januari weve reduc full-year revenu
forecast result revis currenc assumpt posit
impact compar abt guidanc posit impact littl
report sale weve lower revenu project
respons weve decreas sale estim
respect full-year ep expect remain unchang fall-
bottom line modest given compani european cost base well
hedg program revenu forecast decreas slightli ep
project remain report result juli
pleas see page report import disclosur
spin-out proprietari pharma new redux pre-humira
larg diversifi medic product compani competit global franchis
nutrit diagnost medic devic intern brand gener pharmaceut
post-spin ad st jude medic aler busi divest
advanc medic optic unit next five year believ combin abt/stj/
alr busi pois deliv revenu growth ep growth low mid-
teen make standout perform compar medic devic peer believ
may upsid estim potenti out-performance busi unit
better-than-expect contribut stj pipelin product success business-
develop initi blend valuat analysi dcf sum-of-the-part price-to-earnings
support outperform rate expect share outperform market
increas market adopt mitraclip
mri-condit crt-d us crt-p
launch
gross oper margin expans
next five year
 enhanc product
acceler diagnost unit
stronger stj synergi captur alr
acceler recoveri intern
contribut corporate-wide top-lin
persist emerg market headwind
nutrit
franchis four major health care segment one diversifi
large-cap medic devic compani world offer lead product
nutrit diagnost medic devic establish brand gener pharmaceut
approxim compani revenu gener unit state
anoth come western europ canada japan australia remain
emerg market includ india china russia brazil januari
complet separ proprietari research-bas pharmaceut busi
oper independ large-cap pharmaceut compani
compani report cowen compani estim
good gross gross margin oper interest interest net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper restructur non-recur charg dilut share analysisgross end decemb end decemb end decemb cowen
compani report cowen compani estim
laboratori diagnost laboratori diagnost molecular diagnost point diagnost point diabet revenu rhythm manag heart failur rhythm manag heart cardiovascular structur heart cardiovascular structur revenu end decemb end decemb end decemb cowen
compani report cowen compani estim
adjust good adjust gross adjust gross oper incom oper incom interest expens interest net interest expens currenc hedg loss expens net expens pre-tax incom incom tax incom tax net incom adj net incom oper net incom oper ep continu oper ep discontinu oper changeadjust ep oper includ disc ep oper share analysisgross incom -oper cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
risk includ stj alr integr global competit pressur adult
pediatr nutrit busi price pressur procedur volum pressur
stent busi vascular product regulatori time approv mitraclip
 risk time regulatori approv meet demand
hundr product launch emerg market establish pharmaceut
busi meet growth target develop emerg market
meet target margin improv four major segment
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
